News | Heart Valve Technology | March 27, 2019

CMS Proposes Updates for TAVR Coverage

Proposal would expand access to TAVR in Medicare by modernizing the requirements that providers must meet to perform the cardiac procedure under Coverage with Evidence Development

The Centers for Medicare and Medicaid Services (CMS) proposed to update its national coverage policy for transcatheter aortic valve replacement (TAVR). The current national coverage determination, effective May 1, 2012, established CMS coverage for TAVR under Coverage with Evidence Development (CED). Since the finalization of the 2012 national coverage determination, TAVR programs have been established in more than 500 hospitals across the country.

March 27, 2019 — The Centers for Medicare and Medicaid Services (CMS) proposed to update its national coverage policy for transcatheter aortic valve replacement (TAVR). The current national coverage determination, effective May 1, 2012, established CMS coverage for TAVR under Coverage with Evidence Development (CED). Since the finalization of the 2012 national coverage determination, TAVR programs have been established in more than 500 hospitals across the country.

Under the coverage proposal announced this week, CMS would continue to cover TAVR under CED when furnished according to an FDA-approved indication. However, CMS is updating the coverage criteria for hospitals and physicians to begin or maintain a TAVR program. The proposed decision provides more flexibility in how providers can meet the requirements for performing TAVR, while continuing to ensure good health outcomes for patients receiving the procedure.

“CMS must continually refine our policies and requirements in light of emerging evidence,” said CMS Administrator Seema Verma. “Today’s decision updates the requirements for hospitals and physicians to perform TAVR to ensure these requirements are in line with the latest research on patient outcomes, in order to broaden access to care while safeguarding quality and safety for Medicare beneficiaries.”

In developing the proposed decision, CMS met with numerous stakeholders including medical professional societies who continue to recommend requirements for providers to perform a certain volume of heart procedures. The proposed decision includes requirements for providers to perform a certain volume of procedures, given the link between heart procedure volume and patient outcomes in the medical literature and the risks from receiving care in low-volume settings.  However, the proposed decision provides more flexibility in how providers can meet these requirements to reflect the latest evidence on volume and outcomes. The proposal is generally consistent with the 2018 Consensus Statement from the American College of Cardiology (ACC), the American Association for Thoracic Surgery (AATS), the Society for Cardiovascular Angiography and Interventions (SCAI), and the Society of Thoracic Surgeons (STS).

In the proposed decision, CMS also seeks to gather more information about metrics other than volume that could be used to assess quality and safety. CMS is specifically proposing a question regarding the relationship between other metrics and patient health outcomes, which could inform a future change to replace the volume criteria with a different metric.

CMS said the decision was made in response to a formal request and is consistent with recommendations from a meeting of the MEDCAC (Medicare Evidence Development and Coverage Advisory Committee) on July 25, 2018. The MEDCAC provides CMS with an external review of medical literature, technology assessments, public testimony, and other data and information on the benefits, harms and appropriateness of therapies under review. 

CMS is seeking comments on the proposed National Coverage Determination. All public comments may be submitted at www.cms.gov/medicare-coverage-database/indexes/nca-open-for-public-comment-index.aspx. A final decision will be issued no later than 60 days after the conclusion of the 30-day public comment period.

To read the proposed decision, visit the CMS website at: https://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx?NCAId=293


Related Content

News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
News | Heart Valve Technology

May 2, 2025 – New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the ...

Home May 02, 2025
Home
News | Heart Valve Technology

April 28, 2025 — The Society of Thoracic Surgeons (STS) has launched its latest surgical risk calculator designed for ...

Home April 29, 2025
Home
News | Heart Valve Technology

March 30, 2025 — Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data ...

Home March 31, 2025
Home
News | Heart Valve Technology

Feb. 22, 2025 — More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the ...

Home March 04, 2025
Home
News | Heart Valve Technology

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive ...

Home February 18, 2025
Home
News | Heart Valve Technology

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is ...

Home February 18, 2025
Home
Subscribe Now